scholarly journals Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting

2021 ◽  
pp. jrheum.201667
Author(s):  
Carmel Stober ◽  
Deepak R. Jadon ◽  
April W. Armstrong ◽  
Vinod Chandran ◽  
Maarten de Wit ◽  
...  
Keyword(s):  
Risk Factors ◽  
Case Report ◽  
Psoriatic Arthritis ◽  
Treatment Response ◽  
Annual Meeting ◽  
Collaborative Research ◽  
Structural Damage ◽  
Research Network ◽  
The Usa ◽  
Axial Disease

At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.

Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2189-2192 ◽  
Author(s):  
OLIVER FITZGERALD ◽  
CHRISTOPHER T. RITCHLIN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Radiographic Progression ◽  
Clinical Markers ◽  
Sample Collection ◽  
Critical Research ◽  
Specific Protocol ◽  
Radiographic Scoring Methods ◽  
Selection Of

Clinical markers of radiographic progression have been studied in patients with psoriatic arthritis (PsA), and results have clearly confirmed the progression of radiographic damage over a 2-year period. Biomarkers of radiographic progression damage (erosion and new bone formation) have also been identified as a critical research issue in these patients. At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed development of a pivotal observational study (PsA Biodam study) to determine the validity of several soluble biomarkers in predicting structural damage in patients with PsA receiving standard therapies. Specific protocol issues discussed were the inclusion criteria, selection of candidate biomarkers, timing of sample collection, the primary radiographic outcome measure, radiographic scoring methods, possible substudies, and funding strategies.

scholarly journals 161: Risk factors for Recurrent Stillbirth (SB): Results from the Stillbirth Collaborative Research Network (SCRN)

2020 ◽  
Vol 222 (1) ◽  
pp. S116-S117
Author(s):  
Megan Whitham ◽  
Elizabeth Gammon ◽  
Briana C. Chronister ◽  
Amanda Urban ◽  
Robert M. Silver ◽  
...  
Keyword(s):  
Risk Factors ◽  
Collaborative Research ◽  
Research Network

Psoriasis and Psoriatic Arthritis Video Project: An Update from the 2010 GRAPPA Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 421-422 ◽  
Author(s):  
JAMIE L. WOODCOCK ◽  
PHILIP J. MEASE ◽  
KRISTINA CALLIS DUFFIN
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Interobserver Reliability ◽  
Severity Index ◽  
Physician Global Assessment ◽  
Web Based ◽  
Area 5 ◽  
Axial Disease ◽  
Biotechnology Companies ◽  
Demonstration Video

Changes in severity of psoriasis and psoriatic arthritis (PsA) are assessed in clinical trials by a variety of physical examination instruments. At the 2010 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members were updated on the development and availability of modules that teach these instruments. Web-based interactive multimedia presentations for psoriasis assessments have been completed, including modules for Psoriasis Area and Severity Index and Body Surface Area, 5-point and 6-point Physician Global Assessment, the original and modified Nail Psoriasis Severity Index, the Palmar-Plantar Pustular Psoriasis Area and Severity Index, and the Psoriasis Scalp Severity Index. Rheumatology modules will include assessment of tender and swollen joints, and evaluations of enthesitis, dactylitis, and axial disease. Each module will include the background and rationale for each tool, demonstration video of each examination, diagrams and photographs to emphasize teaching points, and an optional examination at the end. The rheumatology modules have been recorded but were not yet available for review at the meeting. The dermatology modules are currently in use by pharmaceutical and biotechnology companies engaged in research on treatments for psoriasis and PsA. The next phase of this project includes analysis of interobserver reliability, translation into languages other than English for international users, and other proposed studies.

Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2013 ◽  
Vol 40 (8) ◽  
pp. 1407-1409 ◽  
Author(s):  
Philip J. Mease ◽  
Wolf-Henning Boehncke ◽  
Dafna D. Gladman
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Research Work ◽  
Screening Tools ◽  
European Academy ◽  
The Status ◽  
Patient Groups ◽  
Peripheral Spondyloarthritis ◽  
Psoriasis Severity

The 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in June 2012 in Stockholm, Sweden, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups from around the world. In this Prologue we introduce discussions that were held among meeting attendees. Prior to the 2012 meeting, 2 GRAPPA members organized a Fellows Symposium adjacent to the European Academy of Dermatology and Venerology meeting in Verona, where they discussed comorbidities and treatments of patients with psoriasis. The 2012 GRAPPA meeting began with a trainee symposium, where 30 rheumatology fellows and dermatology residents presented their research work. Other presentations and discussions included a review of arthritis mutilans; dermatology issues including screening tools for psoriatic arthritis (PsA) and the instruments to measure psoriasis severity; cardiovascular and other comorbidities of psoriasis and PsA; development of criteria to define inflammatory arthritis, enthesitis, dactylitis, and spondylitis; distinctions between peripheral spondyloarthritis and PsA; the status of an ultrasound outcome measure for dactylitis; and updates on several GRAPPA projects, including a study of biomarkers to predict structural damage in PsA, the ongoing video project, and several education initiatives.

Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2021 ◽  
pp. jrheum.201666
Author(s):  
Kristina Callis Duffin ◽  
Alice B. Gottlieb ◽  
Denis O’Sullivan ◽  
Dafna D. Gladman ◽  
Lynne V. McFarland
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Outcome Measures ◽  
Treatment Guidelines ◽  
Clinical Care ◽  
Pustular Psoriasis ◽  
Research Network ◽  
Grant Writing ◽  
Psoriatic Disease ◽  
Travel Restrictions

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2020 in an online format due to travel restrictions during the coronavirus disease 2019 (COVID‑19; caused by SARS-CoV-2) pandemic. The virtual meeting was attended by 351 rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA’s annual meeting focused on the 3 overlapping missions of education, research, and clinical care of psoriatic disease. Trainee sessions this year included the annual trainee symposium and a grant-writing workshop. Plenary sessions included updates on COVID-19 and psoriatic disease from multispecialty and patient perspectives, and updates on pustular psoriasis and associated musculoskeletal manifestations. Progress on research and updates were presented for the following groups: Collaborative Research Network, Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Working Group, International Dermatology Outcome Measures, Composite Measures, Education Committee, and Treatment Guidelines. New this year were 3 concurrent workshops on ultrasound assessment of joints and entheses, magnetic resonance imaging of psoriatic arthritis, and pustular psoriasis efficacy endpoints; 6 “Meet the Expert” sessions; and facilitated “poster tours.” In our prologue, we introduce the papers that summarize this meeting.

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting

2021 ◽  
pp. jrheum.201680
Author(s):  
Denis P. O’Sullivan ◽  
Ingrid Steinkoenig
Keyword(s):  
Annual Meeting ◽  
Collaborative Research ◽  
Treatment Guidelines ◽  
Panel Discussion ◽  
Research Network ◽  
Eleven Patient ◽  
Virtual Group ◽  
Core Set ◽  
Network Update ◽  
Network Project

Eleven Patient Research Partners (PRPs) attended the virtual Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 Annual Meeting. PRPs fully participated in the panel discussion at the 2020 GRAPPA Annual Meeting on the topic of the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2). The members of the PRP group have been involved in many GRAPPA projects over the last year, including work on the GRAPPA–Outcome Measures in Rheumatology (OMERACT) Core Set, GRAPPA’s 2020 Treatment Guidelines update project, and GRAPPA’s Collaborative Research Network project.

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group

2021 ◽  
pp. jrheum.201679
Author(s):  
Ying Ying Leung ◽  
Ana-Maria Orbai ◽  
William Tillett ◽  
Alexis Ogdie ◽  
Lihi Eder ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Physical Function ◽  
Annual Meeting ◽  
Working Group ◽  
Structural Damage ◽  
Short Form ◽  
Core Outcome Set ◽  
Health Assessment ◽  
Working Groups ◽  
Set Up

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group provided updates at the 2020 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. Working groups were set up for the 4 prioritized domains: enthesitis, fatigue, structural damage, and physical function. Two instruments for measurement of physical function were provisionally endorsed: (1) the Health Assessment Questionnaire–Disability Index and (2) the physical functioning domain in the Medical Outcomes Study 36-item Short Form survey.

Utility in Clinical Trials of Magnetic Resonance Imaging for Psoriatic Arthritis: A Report from the GRAPPA 2014 Annual Meeting

2015 ◽  
Vol 42 (6) ◽  
pp. 1044-1047 ◽  
Author(s):  
Mikkel Østergaard ◽  
Daniel Glinatsi ◽  
Susanne Juhl Pedersen ◽  
Inge Juul Sørensen
Keyword(s):  
Magnetic Resonance Imaging ◽  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Annual Meeting ◽  
Structural Damage ◽  
Current Knowledge ◽  
Future Research ◽  
Resonance Imaging ◽  
Research Perspectives

Psoriatic arthritis (PsA) is a heterogeneous disease that involves both peripheral and axial joints and entheses. Magnetic resonance imaging (MRI) allows visualization of the inflammatory components (synovitis, tenosynovitis, enthesitis, periarticular inflammation, and bone marrow edema) as well as structural damage (bone erosion, bone proliferation) in PsA. However, MRI has not been validated as an outcome measure in PsA clinical trials to the same extent as in rheumatoid arthritis. Recently, further validation of the Outcome Measures in Rheumatology (OMERACT) PsA MRI score (PsAMRIS) was presented at the 2014 annual meeting of the Group for Research and Assessment of Psoriatic Arthritis (GRAPPA). In this review, we present the current knowledge within MRI assessment of PsA, particularly peripheral manifestations, as well as different imaging methods and scoring systems, and we discuss future research perspectives.

scholarly journals Artritis Psoriatika

2021 ◽  
Vol 1 (12) ◽  
pp. 868-883
Author(s):  
Faris Rizki Ardhan ◽  
Muhammad Akbar Hanardi ◽  
Dhila Thasliyah ◽  
Visakha Vidyadevi Wiguna ◽  
Ni Putu Yunandari
Keyword(s):  
Risk Factors ◽  
Psoriatic Arthritis ◽  
Pharmacological Treatment ◽  
Structural Damage ◽  
Ideal Body Weight ◽  
Pharmacological Therapy ◽  
The Body ◽  
Physical Trauma ◽  
Treatment And Prevention

To know the risk factors, pharmacological treatment and prevention of psoriatic arthritis. Psoriatic arthritis is a chronic musculoskeletal disease associated with psoriasis. at least 5% of psoriasis patients develop psoriatic arthritis. Globally, the incidence of PsA reaches 133 per 100,000 patient subjects. The annual incidence of PsA is about 2.7 cases per 100 people diagnosed with psoriasis. In Asia, PsA cases increased from 2000 to 2013 with a prevalence (per 100,000 population) of 11.12 to 37.75. Based on a study at Sanglah Hospital Bali found PsA patients as much as 6.3% of psoriasis patients. PsA patients may have clinical features such as peripheral arthritis, enthesitis, dactylitis, skin, nail, and axial involvement. Risk factors for psoriatic arthritis include obesity, physical trauma, smoking, location of psoriasis in the body, education level and genetic factors. Pharmacological treatment of PsA based on the latest guidelines from EULAR 2019 and ACR recommendations. These two guidelines discuss pharmacological treatment based on the patient's clinical picture. The goal of pharmacological therapy is to improve the patient's quality of life by improving symptomatic complaints and preventing structural damage. As a prevention, PsA maintains an ideal body weight, reduces cigarette consumption, and performs detection as an early detection.

Sign in / Sign up

Export Citation Format

Share Document